Preclinical target validation using patient-derived cells
A.M. Edwards(University of Toronto), Kevin Petrecca(Montreal Neurological Institute and Hospital), Phil Barker(Montreal Neurological Institute and Hospital), C.H. Arrowsmith(Ontario Institute for Cancer Research), Stefan Knapp(Goethe University Frankfurt), Mário Henrique Bengtson(Universidade Estadual de Campinas (UNICAMP)), Trevor Howe(Janssen (United Kingdom)), Rónán C. O’Hagan(Merck & Co., Inc., Rahway, NJ, USA (United States)), C. Bountra(University of Oxford), Katlin B. Massirer(Universidade Estadual de Campinas (UNICAMP)), Senthil K. Muthuswamy(Beth Israel Deaconess Medical Center), Alex MacKenzie(University of Ottawa), Dalia Barsyte(University of Toronto), Anuk Das(Springhouse), John Isaac(Wellcome Trust), Udo Oppermann(Oxford BioMedica (United Kingdom)), James Ellis(University of Toronto), Edward A. Fon(Montreal Neurological Institute and Hospital), Kirk Clark(Novartis (United States)), Evelyne Lima‐Fernandes(University of Toronto), Dashyant Dhanak(Wilmington University), Paul Bowness(Nuffield Orthopaedic Centre), Julian C. Knight(Centre for Human Genetics), Mark E. Bunnage(Vertex Pharmaceuticals (United States)), Marc Feldmann(University of Oxford), Valeria R. Fantin(AVEO Oncology (United States)), O. Gileadi(University of Oxford), Wen‐Hwa Lee(The University of Texas Health Science Center at San Antonio), Carolyn Buser‐Doepner(GlaxoSmithKline (United States)), Peter B. Dirks(Unknown), Panagiotis Prinos(University of Toronto), Nada Jabado(McGill University), Lars Klareskog(Karolinska University Hospital), Nils Ostermann(Novartis (Switzerland)), Catherine O′Brien(University Health Network), Jagdeep Nanchahal(Nuffield Orthopaedic Centre), Tetsuyuki Maruyama(Takeda (Japan)), Cindy Bell, Michael D. Taylor(Hospital for Sick Children), Dhavalkumar D. Patel(Duke University), Andrew Carr(University of Oxford), Christopher L. Carpenter(GlaxoSmithKline (United States)), Anke Mueller‐Fahrnow(Bayer (Germany)), Kym M. Boycott(Children's Hospital of Eastern Ontario), John C. Marshall(St. Michael's Hospital), Christopher M. Flores(Janssen (United States)), Per‐Johan Jakobsson(Karolinska University Hospital), M. Sundström(Karolinska University Hospital), Donald E. Frail(Allergan (United States)), Ingrid E. Lundberg(Karolinska University Hospital)
Cited by 54
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
|The Lancet|2004|1.8k
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
|Cell|2012|1.7k
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
|Pharmacology & Therapeutics|2007|1.6k